From Plums AGM1 summary referring to the Chinese payment; “ however he indicated that there were more commercial discussions surrounding this, the payment is tied to other potential commercial arrangements. ” It would take something important for the Chairman of Newsummit to visit London in person so the additional commercial discussions are interesting because it could be related to any of the portfolio.
DaveW58 consumer products do not require testing as they are natural products of course medical grade pharma products will as you say. Royalties are there to pick up early revenue from the consumer therapeutic market.
Top ten cannabis companies in the US are attached. It includes GW Pharma that has Epidialex and is valued at US3.15 bn. Not inconsequential values and given the widespread potential use of cannabinoids probably more valuable than NXP002.
3 other non execs on the board. Kirk was a presumably a pr appointment to satisfy the largest shareholder in the early days. NFX now past that given two drugs ready to commercialise and more on the way.
The RNS implies this cannabinoid will be suitable for many products ie part of the mix to enhance products currently available not necessarily a stand alone development. It is immediately available manufacture and distribution is key.
So JD has convinced broker Stiefel whose smallest client is £470m (with £70m Mcap) and Trade desk/Zandr AppNexus who require a minimum income stream from accounts to take on Bids presumably with the prospect in the near term they will stack up with their other clients. So what is next to add to the portfolio with Epic et al. Tencent would unlock those doors or are there others ? https://geoshen.com/posts/15-largest-video-game-publishers-by-revenue